15. LIFE ON LAND

Establishment Labs (NASDAQ:ESTA) Shares Gap Down to $55.89 – Defense World

Written by Amanda

Establishment Labs (NASDAQ:ESTA) Shares Gap Down to $55.89  Defense World

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTAGet Rating) gapped down before the market opened on Friday . The stock had previously closed at $55.89, but opened at $53.93. Establishment Labs shares last traded at $53.93, with a volume of 4 shares changing hands.

A number of brokerages have weighed in on ESTA. Cowen lifted their price target on shares of Establishment Labs from $95.00 to $125.00 in a research report on Friday, April 22nd. The Goldman Sachs Group reduced their price target on shares of Establishment Labs from $78.00 to $67.00 and set a “neutral” rating on the stock in a research report on Monday, March 21st. Cowen lifted their price target on shares of Establishment Labs from $95.00 to $125.00 in a research report on Friday, April 22nd. Finally, BTIG Research reduced their target price on shares of Establishment Labs from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, June 24th.

The business’s 50-day moving average price is $58.62 and its 200 day moving average price is $60.87. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.01 and a quick ratio of 2.23. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -33.52 and a beta of 1.12.

Establishment Labs (NASDAQ:ESTAGet Rating) last posted its earnings results on Monday, May 9th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.18. Establishment Labs had a negative net margin of 29.77% and a negative return on equity of 70.10%. The business had revenue of $38.45 million for the quarter, compared to analysts’ expectations of $35.40 million. During the same period in the previous year, the company posted ($0.29) earnings per share. As a group, sell-side analysts expect that Establishment Labs Holdings Inc. will post -1.32 earnings per share for the current year.

In related news, major shareholder Jw Asset Management, Llc purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The shares were purchased at an average cost of $57.52 per share, with a total value of $575,200.00. Following the completion of the acquisition, the insider now directly owns 3,187,485 shares of the company’s stock, valued at approximately $183,344,137.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders purchased 50,000 shares of company stock worth $3,299,700 over the last ninety days. 13.08% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of ESTA. Madryn Asset Management LP acquired a new stake in Establishment Labs in the fourth quarter valued at $49,475,000. American Century Companies Inc. acquired a new stake in Establishment Labs in the first quarter valued at $14,516,000. Millennium Management LLC increased its stake in Establishment Labs by 69.8% during the fourth quarter. Millennium Management LLC now owns 514,821 shares of the company’s stock valued at $34,797,000 after purchasing an additional 211,677 shares during the last quarter. CWM LLC bought a new stake in Establishment Labs during the fourth quarter valued at $9,435,000. Finally, JPMorgan Chase & Co. increased its stake in Establishment Labs by 321.5% during the fourth quarter. JPMorgan Chase & Co. now owns 160,508 shares of the company’s stock valued at $10,848,000 after purchasing an additional 122,427 shares during the last quarter. 77.79% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Company Profile (NASDAQ:ESTA)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.

See Also

Receive News & Ratings for Establishment Labs Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Establishment Labs and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai

Leave a Comment